• Price (USD)264.63
  • Today's Change0.66 / 0.25%
  • Shares traded1.69m
  • 1 Year change+2.27%
  • Beta0.6428
Data delayed at least 15 minutes, as of Jan 21 2022 21:10 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through three business segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

  • Revenue in USD (TTM)20.25bn
  • Net income in USD2.00bn
  • Incorporated1906
  • Employees75.00k
  • Location
    Becton Dickinson and Co1 Becton DrFRANKLIN LAKES 07417-1815United StatesUSA
  • Phone+1 (201) 847-6800
  • Websitehttp://www.bd.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BDX:NYQ since
Scanwell Health IncDeal completed21 Dec 202121 Dec 2021Deal completed4.84%--
Tissuemed LtdDeal completed09 Dec 202109 Dec 2021Deal completed7.38%--
Venclose IncDeal completed02 Dec 202102 Dec 2021Deal completed9.50%--
Tepha IncDeal completed27 Jul 202127 Jul 2021Deal completed6.09%--
Velano Vascular IncDeal completed20 Jul 202120 Jul 2021Deal completed7.03%--
Data delayed at least 15 minutes, as of Jan 21 2022 21:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
DexCom, Inc.2.32bn529.30m40.91bn5.50k79.3519.1566.0317.645.325.3223.2622.040.53882.545.16421,672.7012.305.7814.376.7869.7766.0922.827.984.503.860.45190.0030.5436.81388.23--42.98--
Baxter International Inc12.45bn1.21bn43.20bn50.00k36.214.9320.753.472.382.3824.3817.520.6243.736.11249,020.006.1310.837.4313.3139.9141.889.8317.191.7815.440.403220.452.743.2136.5622.90-4.89-5.54
Boston Scientific Corporation11.47bn1.10bn61.23bn38.00k55.953.7227.925.340.7680.7688.0111.550.36572.477.02301,842.103.693.034.183.7866.9669.7010.097.171.15--0.35560.00-7.665.80-119.23--0.3484--
Edwards Lifesciences Corp5.09bn1.48bn70.33bn14.90k48.2712.6943.6413.812.332.338.048.880.6811.648.86341,912.8019.7514.6922.4717.4875.7474.5129.0021.522.87--0.0970.000.880911.96-21.5610.7230.77--
Becton Dickinson and Co20.25bn2.00bn75.43bn75.00k38.653.1817.653.736.856.8569.3683.230.37543.868.27269,960.003.882.614.392.9646.5646.6310.337.490.90137.020.426572.7918.2910.16161.0215.4511.394.69
Stryker Corporation16.67bn1.90bn96.04bn43.00k51.206.7833.405.764.974.9743.6437.590.50181.816.36387,651.205.727.326.638.7262.6565.6911.4013.781.35--0.471539.73-3.587.61-23.242.1312.5210.76
Intuitive Surgical, Inc.5.71bn1.70bn96.21bn8.08k57.818.0560.5016.854.664.6615.6133.480.46192.958.00--13.9813.9715.6215.6069.3268.8330.2629.075.86------31.0116.1054.4617.28----
Data as of Jan 21 2022. Currency figures normalised to Becton Dickinson and Co's reporting currency: US Dollar USD

Institutional shareholders

36.47%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202122.96m8.06%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 202115.44m5.42%
Wellington Management Co. LLPas of 30 Sep 202114.49m5.08%
BlackRock Fund Advisorsas of 30 Sep 202113.37m4.69%
SSgA Funds Management, Inc.as of 30 Sep 202112.22m4.29%
Morgan Stanley Investment Management Ltd.as of 30 Sep 20218.18m2.87%
Parnassus Investmentsas of 30 Sep 20214.71m1.65%
Massachusetts Financial Services Co.as of 30 Sep 20214.44m1.56%
Geode Capital Management LLCas of 30 Sep 20214.35m1.53%
Generation Investment Management LLPas of 30 Sep 20213.79m1.33%
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.